The COVID-19 pandemic sparked the reimagining of the pharmaceutical industry, illustrating the possibilities — and benefits — of fully remote commerce. Among other things, we’ve learned that bringing drugs to market needn’t be a 10-year slog and that pharma can be smarter, faster, and more efficient.
Saul Helman, MD, and David Weiss outline three lessons for the pharmaceutical industry to carry forward post-COVID:
Infuse agility and responsiveness into the sales force.
Take advantage of opportunities to expedite the path to market.
Simplify the supply chain with proactive strategies to address its complexities.